Andrew P. Duker
YOU?
Author Swipe
View article: Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease
Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease Open
Importance The Implantable Neurostimulator for the Treatment of Parkinson’s Disease (INTREPID) trial was a randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of Parki…
View article: Studying Rare Movement Disorders: From Whole-Exome Sequencing to New Diagnostic and Therapeutic Approaches in a Modern Genetic Clinic
Studying Rare Movement Disorders: From Whole-Exome Sequencing to New Diagnostic and Therapeutic Approaches in a Modern Genetic Clinic Open
Background: Rare movement disorders often have a genetic etiology. New technological advances have increased the odds of achieving genetic diagnoses: next-generation sequencing (NGS) (whole-exome sequencing—WES; whole-genome sequencing—WGS…
View article: Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology‐Proven Cases
Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology‐Proven Cases Open
Background Bradykinesia is a cardinal feature in parkinsonisms. No study has assessed the differential features of bradykinesia in patients with pathology‐proven synucleinopathies and tauopathies. Objective We examined whether bradykinesia…
View article: Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease
Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease Open
Enterin, Inc.
View article: The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study Open
ClinicalTrials.gov identifier: NCT01897896.
View article: Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial Open
View article: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial
Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial Open
SIGNAL is a multicenter, randomized, double-blind, placebo-controlled phase 2 study (no. NCT02481674) established to evaluate pepinemab, a semaphorin 4D (SEMA4D)-blocking antibody, for treatment of Huntington’s disease (HD). The trial enro…
View article: Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease Open
ClinicalTrials.gov Identifier: NCT03205488.
View article: Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial Open
SRX246 is a vasopressin (AVP) 1a receptor antagonist that crosses the blood-brain barrier. It reduced impulsive aggression, fear, depression and anxiety in animal models, blocked the actions of intranasal AVP on aggression/fear circuits in…
View article: Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP) Open
Ongoing biomarker development programs have been designed to identify serologic or imaging signatures of clinico-pathologic entities, assuming distinct biological boundaries between them. Identified putative biomarkers have exhibited large…
View article: Current Directions in Deep Brain Stimulation for Parkinson’s Disease—Directing Current to Maximize Clinical Benefit
Current Directions in Deep Brain Stimulation for Parkinson’s Disease—Directing Current to Maximize Clinical Benefit Open
View article: The “broken wishbone” splenial sign: A diagnostic hallmark for SPG54 spastic ataxia
The “broken wishbone” splenial sign: A diagnostic hallmark for SPG54 spastic ataxia Open
View article: Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease
Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease Open
Treatment with STN DBS for patients with Parkinson disease with LRRK2, GBA, or PRKN mutations appears to be associated with similar motor outcomes but different changes in dopaminergic dose, activities of daily living, motor complications,…
View article: Nutritional ketosis for mild cognitive impairment in Parkinson's disease: A controlled pilot trial
Nutritional ketosis for mild cognitive impairment in Parkinson's disease: A controlled pilot trial Open
View article: Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects
Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects Open
View article: Tablet-Based Application for Objective Measurement of Motor Fluctuations in Parkinson Disease
Tablet-Based Application for Objective Measurement of Motor Fluctuations in Parkinson Disease Open
Background: The motor subscale of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS-III) has limited applicability for the assessment of motor fluctuations in the home setting. Methods:
View article: Motor, cognitive, and functional declines contribute to a single progressive factor in early HD
Motor, cognitive, and functional declines contribute to a single progressive factor in early HD Open
Use of a composite motor, cognitive, and global functional clinical outcome measure in HD provides an improved measure of clinical progression more related to measures of progressive brain atrophy and provides an opportunity for enhanced c…
View article: A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease Open
This article provides Class I evidence that CoQ does not slow the progressive functional decline of patients with HD.
View article: Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease Open
View article: Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease
Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease Open
View article: Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease Open
clinicaltrials.gov Identifier: NCT01795859.
View article: Misleading Imaging and Clinical Features in Pathology‐Proven Corticobasal Degeneration
Misleading Imaging and Clinical Features in Pathology‐Proven Corticobasal Degeneration Open
Tremorless, axial-predominant parkinsonism with impaired balance and ocular dysmotility suggests PSP. Imaging features of olivopontocerebellar atrophy (OPCA) suggest the cerebellar variant of MSA (MSA-C). We present a case with these clini…
View article: Dopamine transporter scanning in the evaluation of patients with suspected Parkinsonism: a case-based user’s guide
Dopamine transporter scanning in the evaluation of patients with suspected Parkinsonism: a case-based user’s guide Open
Given the wide range of manifestations of parkinsonism and its mimics, the diagnosis may remain elusive or be misattributed in some patients. Dopamine transporter (DAT) single photon emission computed tomography (SPECT) (DaTscan), an imagi…